158 related articles for article (PubMed ID: 38160990)
1. An iodine‑labelled Antibody-drug conjugate PET probe for noninvasive monitoring of Nectin-4 expression in urothelial carcinoma.
Ren Y; Liu T; Li S; Ma X; Xia L; Wang P; Guo Q; Yao Y; Hou X; Sheng X; Zhu H; Yang Z
Int J Pharm; 2024 Feb; 651():123756. PubMed ID: 38160990
[TBL] [Abstract][Full Text] [Related]
2. Targeting nectin-4 by antibody-drug conjugates for the treatment of urothelial carcinoma.
Wong JL; Rosenberg JE
Expert Opin Biol Ther; 2021 Jul; 21(7):863-873. PubMed ID: 34030536
[TBL] [Abstract][Full Text] [Related]
3. Enfortumab Vedotin-ejfv: A First-in-Class Anti-Nectin-4 Antibody-Drug Conjugate for the Management of Urothelial Carcinoma.
Halford Z; Anderson MK; Clark MD
Ann Pharmacother; 2021 Jun; 55(6):772-782. PubMed ID: 32945172
[TBL] [Abstract][Full Text] [Related]
4. [Antibody-drug conjugates directed against NECTIN-4 as a new treatment option for patients with metastatic urothelial carcinoma].
Klümper N; Eckstein M; Kunath F; Heidegger I; Becker C; Rausch S;
Urologie; 2023 Nov; 62(11):1193-1199. PubMed ID: 37658236
[TBL] [Abstract][Full Text] [Related]
5. Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E-based Antibody-Drug Conjugate for Treatment of Nectin-4-expressing Cancers.
Zhou W; Fang P; Yu D; Ren H; You M; Yin L; Mei F; Zhu H; Wang Z; Xu H; Cao Y; Sun X; Xu X; Bi J; Wang J; Ma L; Wang X; Chen L; Zhang Y; Cen X; Zhu X; Lou L; Liu D; Tan X; Yang J; Meng T; Shen J
Mol Cancer Ther; 2023 Aug; 22(8):913-925. PubMed ID: 37196158
[TBL] [Abstract][Full Text] [Related]
6. Enfortumab vedotin in the treatment of urothelial cancers and beyond.
Wong RL; Yu EY
Future Oncol; 2022 Sep; 18(27):3067-3084. PubMed ID: 36004667
[TBL] [Abstract][Full Text] [Related]
7. NECTIN-4 targeted theranostics for urothelial cancer: getting ready for primetime?
Filippi L; Schillaci O
Expert Rev Anticancer Ther; 2024; 24(1-2):1-4. PubMed ID: 37994866
[TBL] [Abstract][Full Text] [Related]
8. First-in-Human Study of the Radioligand 68Ga-N188 Targeting Nectin-4 for PET/CT Imaging of Advanced Urothelial Carcinoma.
Duan X; Xia L; Zhang Z; Ren Y; Pomper MG; Rowe SP; Li X; Li N; Zhang N; Zhu H; Yang Z; Sheng X; Yang X
Clin Cancer Res; 2023 Sep; 29(17):3395-3407. PubMed ID: 37093191
[TBL] [Abstract][Full Text] [Related]
9. Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance.
Klümper N; Ralser DJ; Ellinger J; Roghmann F; Albrecht J; Below E; Alajati A; Sikic D; Breyer J; Bolenz C; Zengerling F; Erben P; Schwamborn K; Wirtz RM; Horn T; Nagy D; Toma M; Kristiansen G; Büttner T; Hahn O; Grünwald V; Darr C; Erne E; Rausch S; Bedke J; Schlack K; Abbas M; Zschäbitz S; Schwab C; Mustea A; Adam P; Manseck A; Wullich B; Ritter M; Hartmann A; Gschwend J; Weichert W; Erlmeier F; Hölzel M; Eckstein M
Clin Cancer Res; 2023 Apr; 29(8):1496-1505. PubMed ID: 36534531
[TBL] [Abstract][Full Text] [Related]
10. Intertriginous erythema associated with enfortumab vedotin, a nectin-4-targeting antibody-drug conjugate, in a case with metastatic urothelial cancer: Immunohistochemical evidence for molecular-targeted eruption.
Hasegawa T; Oyama N; Kasamatsu H; Chino T; Taga M; Hasegawa M
J Dermatol; 2022 Dec; 49(12):e453-e454. PubMed ID: 36052729
[No Abstract] [Full Text] [Related]
11. Metastatic Bladder Cancer Expression and Subcellular Localization of Nectin-4 and Trop-2 in Variant Histology: A Rapid Autopsy Study.
Ghali F; Vakar-Lopez F; Roudier MP; Garcia J; Arora S; Cheng HH; Schweizer MT; Haffner MC; Lee JK; Yu EY; Grivas P; Montgomery B; Hsieh AC; Wright JL; Lam HM
Clin Genitourin Cancer; 2023 Dec; 21(6):669-678. PubMed ID: 37344281
[TBL] [Abstract][Full Text] [Related]
12. Near-infrared photoimmunotherapy targeting Nectin-4 in a preclinical model of bladder cancer.
Fukushima H; Takao S; Furusawa A; Valera Romero V; Gurram S; Kato T; Okuyama S; Kano M; Choyke PL; Kobayashi H
Cancer Lett; 2024 Mar; 585():216606. PubMed ID: 38272345
[TBL] [Abstract][Full Text] [Related]
13. BT8009; A Nectin-4 Targeting Bicycle Toxin Conjugate for Treatment of Solid Tumors.
Rigby M; Bennett G; Chen L; Mudd GE; Harrison H; Beswick PJ; Van Rietschoten K; Watcham SM; Scott HS; Brown AN; Park PU; Campbell C; Haines E; Lahdenranta J; Skynner MJ; Jeffrey P; Keen N; Lee K
Mol Cancer Ther; 2022 Dec; 21(12):1747-1756. PubMed ID: 36112771
[TBL] [Abstract][Full Text] [Related]
14. Metastatic Penile Squamous Cell Carcinoma Responsive to Enfortumab Vedotin.
Fahey CC; Nebhan CA; York S; Davis NB; Hurley PJ; Gordetsky JB; Schaffer KR
Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003302
[TBL] [Abstract][Full Text] [Related]
15. Nectin-4 is widely expressed in head and neck squamous cell carcinoma.
Sanders C; Lau JF; Dietrich D; Strieth S; Brossart P; Kristiansen G
Oncotarget; 2022 Oct; 13():1166-1173. PubMed ID: 36268557
[TBL] [Abstract][Full Text] [Related]
16. Enfortumab vedotin-ejfv for the treatment of advanced urothelial carcinoma.
Mantia CM; Sonpavde G
Expert Rev Anticancer Ther; 2022 May; 22(5):449-455. PubMed ID: 35466857
[TBL] [Abstract][Full Text] [Related]
17. Associations of TACSTD2/TROP2 and NECTIN-4/NECTIN-4 with molecular subtypes, PD-L1 expression, and FGFR3 mutational status in two advanced urothelial bladder cancer cohorts.
Bahlinger V; Branz A; Strissel PL; Strick R; Lange F; Geppert CI; Klümper N; Hölzel M; Wach S; Taubert H; Sikic D; Wullich B; Angeloni M; Ferrazzi F; Diehl L; Kovalenko M; Elboudwarej E; Jürgensmeier JM; Hartmann A; Eckstein M
Histopathology; 2024 Apr; 84(5):863-876. PubMed ID: 38196202
[TBL] [Abstract][Full Text] [Related]
18. Nectin-4: a Tumor Cell Target and Status of Inhibitor Development.
Bouleftour W; Sargos P; Magne N
Curr Oncol Rep; 2023 Mar; 25(3):181-188. PubMed ID: 36696077
[TBL] [Abstract][Full Text] [Related]
19. Clinical and direct immunofluorescence characteristics of cutaneous toxicity associated with enfortumab vedotin.
Penny CL; Quow K; Rundle CW; Al-Rohil RN; Cardones AR; Kheterpal MK; Fresco AI
Br J Dermatol; 2022 Jul; 187(1):126-127. PubMed ID: 35048357
[TBL] [Abstract][Full Text] [Related]
20. Enfortumab Vedotin, a fully human monoclonal antibody against Nectin 4 conjugated to monomethyl auristatin E for metastatic urothelial Carcinoma.
McGregor BA; Sonpavde G
Expert Opin Investig Drugs; 2019 Oct; 28(10):821-826. PubMed ID: 31526130
[No Abstract] [Full Text] [Related]
[Next] [New Search]
